Merck & Co Inc (N:MRK)
Business Focus: Pharmaceuticals
| Sector: Healthcare | Industry: Pharmaceuticals |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 2000 Galloping Hill Road KENILWORTH NJ 07033 |
| Tel: | N/A |
| Website: | https://www.merck.com |
| IR: | See website |
| Key People | ||
| Robert M. Davis Chairman of the Board, President, Chief Executive Officer | Lisa LeCointe-Cephas Senior Vice President, Chief Ethics and Compliance Officer | Steven C. Mizell Executive Vice President, Chief Human Resources Officer |
| David M. Williams Executive Vice President, Chief Information and Digital Officer | Jennifer L. Zachary Executive Vice President, General Counsel, Corporate Secretary | Sanat Chattopadhyay Executive Vice President and President - Merck Manufacturing Division |
| Richard R. Deluca Executive Vice President, President - Merck Animal Health | Cristal N. Downing Executive Vice President, Chief Communications and Public Affairs Officer | Dean Y. Li Executive Vice President, President - Merck Research Laboratories | Dalton E. Smart Senior Vice President Finance '�� Global Controller |
| Business Overview |
| Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company's Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. It sells these human health pharmaceutical products to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, and health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. The Company's lead candidate, MK-6070, is a T-cell engager targeting delta-like ligand 3 (DLL3), an inhibitory canonical Notch ligand. |
| Financial Overview |
| For the fiscal year ended 31 December 2023, Merck & Co Inc revenues increased 1% to $60.12B. Net income decreased 97% to $365M. Revenues reflect Merck Pharmaceutical segment increase of 2% to $58.52B, China (Country) segment increase of 31% to $6.8B, United States segment increase of 5% to $28.48B. Net income was offset by Research and development - Balancing increase from $11.82B to $29.75B (expense). |
| Employees: | 72,000 as of Dec 31, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $345,173M as of Dec 31, 2023 |
| Annual revenue (TTM): | $60,114M as of Dec 31, 2023 |
| EBITDA (TTM): | $10,035M as of Dec 31, 2023 |
| Net annual income (TTM): | $365.00M as of Dec 31, 2023 |
| Free cash flow (TTM): | $1,698M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | $27,962M as of Dec 31, 2023 |
| Shares outstanding: | 2,533,028,189 as of Apr 1, 2024 |
| Index Membership: | S&P 500, Dow Industry |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.